Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | PKM | P14618 | 2/20 | 1.00 |
| ▸ | APEX1 | P27695 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | MIF | P14174 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 1/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.71 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.71 |
| ▸ | CBS | P35520 | 2/20 | 0.71 |
| ▸ | PARP1 | P09874 | 9/20 | 0.67 |
| ▸ | PARP2 | Q9UGN5 | 6/20 | 0.67 |
| ▸ | APP | P05067 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29574181 | 1.00 | PTPN1 (1.00) | PTPN1KDM4ECYP3A4MAPTPKM | |
| SCHEMBL17301661 | 0.95 | KDM4E (0.90) | PTPN1KDM4ECYP3A4MAPTPKM | |
| Cupressuflavone SCHEMBL31670258 | 0.84 | CBS (1.00) | PTPN1KDM4ECYP3A4MAPTPKM | |
| SCHEMBL2565483 | 0.84 | CYP3A4 (0.78) | PTPN1KDM4ECYP3A4MAPTPKM | |
| Cupressuflavone SCHEMBL505213 | 0.84 | CBS (1.00) | PTPN1KDM4ECYP3A4MAPTPKM | |
| SCHEMBL30684642 | 0.84 | CYP3A4 (0.78) | PTPN1KDM4ECYP3A4MAPTPKM | |
| Cupressuflavone SCHEMBL4650575 | 0.83 | CBS (0.97) | PTPN1KDM4ECYP3A4MAPTPKM | |
| SCHEMBL15948836 | 0.82 | PTPN1 (0.77) | PTPN1KDM4ECYP3A4MAPTPKM | |
| Agathisflavone SCHEMBL30637380 | 0.80 | CBS (1.00) | PTPN1KDM4ECYP3A4MAPTPKM | |
| Agathisflavone SCHEMBL616142 | 0.80 | CBS (1.00) | PTPN1KDM4ECYP3A4MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104274831-A | Composition based on naturally derived peptide and inflammation inhibitor and/or anti-oxidation compound | SOO TUCK POOI | 2015-01-14 | — | — | CN | claimed |
| CN-103221056-A | Electronically Modified Reaction Intermediates | MARKOU DEMETRIOS | 2013-07-24 | — | — | CN | claimed |
| EP-2603225-A2 | ELECTRONICALLY MODIFIED REACTION INTERMIDEATES | Markou, Demetrios (US) | 2013-06-19 | — | — | EP | claimed |
| WO-2012024196-A2 | A NOVEL METHOD FOR CREATING, SUSPENDING AND STABILIZING ELECTRONICALLY MODIFIED REACTION INTERMIDEATES | MARKOU DEMETRIOS (US) | 2012-02-23 | — | — | WO | claimed |
| US-20120039796-A1 | Novel method for creating, suspending and stabilizing electronically modified oxygen derivatives, along with creating, suspending and stabilizing electronically modified reaction intermediates, in a bio compatible fluorocarbon suspension, for the purpose of inducing a cascading immune response in mammalian patients | MARKOU DEMETRIOS (US) | 2012-02-16 | — | — | US | claimed |
| CN-101049301-A | Pharmaceutical preparation of biflavone compound for anti gout | HUIBEI COLLEGE OF CHINESE MEDI (CN) | 2007-10-10 | — | — | CN | claimed |
| US-20020068757-A1 | Biflavanoids and derivatives thereof as antiviral agents | ADVANCED LIFE SCIENCES, INC. | 2002-06-06 | — | — | US | claimed |
| US-6399654-B1 | ADMINISTERING MIXTURE OF VIRICIDE AND BIOFLAVANOID | ADVANCED LIFE SCIENCES, INC. | 2002-06-04 | — | — | US | claimed |
| WO-1998046238-A1 | BIFLAVINOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS, ALONE OR IN COMBINATION WITH AT LEAST ONE KNOWN ANTIVIRAL AGENT | MEDICHEM RESEARCH, INC. (US) | 1998-10-22 | — | — | WO | claimed |
| EP-0833631-A1 | BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS | MEDICHEM RESEARCH, INC. (US) | 1998-04-08 | — | — | EP | claimed |
| WO-1997000679-A1 | BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS | MEDICHEM RESEARCH, INC. (US) | 1997-01-09 | — | — | WO | claimed |
| EP-4580594-A1 | ANTIOXIDANT COMPOSITION COMPRISING 5-DEOXYFLAVONOIDS | AnalytiCon Discovery - Zweigniederlassung der BRAIN Biotech AG (DE) | 2025-07-09 | — | — | EP | disclosed |
| US-20240389587-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING PHYTOPATHOGENIC INFECTIONS | INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (INRAE) (FR) | 2024-11-28 | — | — | US | disclosed |
| WO-2024046834-A1 | ANTIOXIDANT COMPOSITION COMPRISING 5-DEOXYFLAVONOIDS | ANALYTICON DISCOVERY GMBH (DE) | 2024-03-07 | — | — | WO | disclosed |
| EP-4331564-A1 | ANTIOXIDANT COMPOSITION COMPRISING 5-DEOXYFLAVONOIDS | Analyticon Discovery GmbH (DE) | 2024-03-06 | — | — | EP | disclosed |
| US-5773462-A | INFLUENZA THERAPY | MEDICHEM RESEARCH, INC. (US) | 1998-06-30 | — | — | US | disclosed |
| EP-0833631-A1 | BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS | MEDICHEM RESEARCH, INC. (US) | 1998-04-08 | — | — | EP | disclosed |
| EP-0833631-A1 | BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS | MEDICHEM RESEARCH, INC. (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1997000679-A1 | BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS | MEDICHEM RESEARCH, INC. (US) | 1997-01-09 | — | — | WO | disclosed |
| WO-1997000679-A1 | BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS | MEDICHEM RESEARCH, INC. (US) | 1997-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068757-A1 | Biflavanoids and derivatives thereof as antiviral agents | HK2, GYS2, HK1 | PTPN1 1427/4885KDM4E 782/4885CYP3A4 533/4885 |
| US-20240389587-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING PHYTOPATHOGENIC INFECTIONS | XBP1, ERN1, ERN2 | PTPN1 2079/4885KDM4E 2982/4885CYP3A4 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.